FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206446> ?p ?o ?g. }

• W4387206446 endingPage "e45" @default.
• W4387206446 startingPage "e45" @default.
• W4387206446 abstract "The combination of accelerated hyperfractionated thoracic radiotherapy (AHF-TRT) of 45 Gy and concurrent chemotherapy is the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dose and fractionation remain controversial. We herein report the results of a phase II study investigating the utility of dose escalation to 54 Gy on AHF-RT for LS-SCLC.We enrolled patients ≤80 years old with treatment-naïve confirmed LS-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The radiation dose was 54 Gy delivered in 36 fractions in 18 treatment days over 3.6 weeks. The chemotherapy regimens were PE (cisplatin and etoposide)- or CE (carboplatin and etoposide)-based. AHF-TRT was given in 2 phases: patients initially received 36 Gy to the gross tumor plus uninvolved mediastinal nodes, followed by a boost to the gross tumor of 18 Gy. All patients were treated with three-dimensional conformal radiation therapy with multiple fields to reduce the elevated dose volume to the surrounding tissues, such as the lungs and esophagus, as much as possible. All patients were evaluated for the overall survival (OS), progression-free survival (PFS), and non-hematological toxicity.Between 2013 and 2016, a total of 13 patients were enrolled in the present study. All the patients were assessable for the response and toxicity. The median age was 67 (range, 54-78) years old, and 9 patients were male, while 4 were female. Twelve patients had a ECOG performance status of 0. The numbers of patients with Stage IIA, IIB, IIIA, and IIIB disease were one, one, eight, and three, respectively. The median follow-up for all patients was 79 (range, 13-107) months, and that for surviving patients was 90 (range, 79-107) months. The patterns of failure were locoregional-only recurrence in 0% (0 patients), both locoregional and distant in 15.4% (2 patients), and distant-only in 30.8% (4 patients). Recurrence from the elective nodal irradiation area was seen in 0% (0 patients). The 1-, 3-, 5-, and 7-year OS rates were 100%, 76.9%, 53.9%, and 44.9%, respectively, and the median OS was 83.0 months. The 1-, 3-, 5-, and 7-year PFS rates were 76.9%, 53.9%, 53.9%, and 44.9%, respectively, and the median PFS was 83.0 months. No patient experienced a grade ≥3 non-hematological adverse effect, such as esophagitis or pneumonitis, during treatment or follow-up. Grade 2 pneumonitis was observed in 2 patients (15.4%), Grade 2 esophagitis was observed in 12 patients (92.3%), and Grade 2 esophageal pain was observed in 2 patients (15.4%).In this study, AHF-TRT of 54 Gy with concurrent PE- or CE-based regimens resulted in a good OS and PFS without increasing severe toxicity. Although this regimen needs to be evaluated in more patients to fully confirm its efficacy, these outcomes suggest that dose escalation to 54 Gy may be a promising radical treatment for LS-SCLC." @default.
• W4387206446 created "2023-09-30" @default.
• W4387206446 creator A5004085793 @default.
• W4387206446 creator A5006753655 @default.
• W4387206446 creator A5018762174 @default.
• W4387206446 creator A5034461650 @default.
• W4387206446 creator A5063898828 @default.
• W4387206446 creator A5064186453 @default.
• W4387206446 creator A5075894849 @default.
• W4387206446 creator A5086278068 @default.
• W4387206446 date "2023-10-01" @default.
• W4387206446 modified "2023-10-17" @default.
• W4387206446 title "Long-Term Results of a Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy with Dose Escalation to 54 Gy for Limited-Stage Small-Cell Lung Cancer" @default.
• W4387206446 doi "https://doi.org/10.1016/j.ijrobp.2023.06.747" @default.
• W4387206446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785450" @default.
• W4387206446 hasPublicationYear "2023" @default.
• W4387206446 type Work @default.
• W4387206446 citedByCount "0" @default.
• W4387206446 crossrefType "journal-article" @default.
• W4387206446 hasAuthorship W4387206446A5004085793 @default.
• W4387206446 hasAuthorship W4387206446A5006753655 @default.
• W4387206446 hasAuthorship W4387206446A5018762174 @default.
• W4387206446 hasAuthorship W4387206446A5034461650 @default.
• W4387206446 hasAuthorship W4387206446A5063898828 @default.
• W4387206446 hasAuthorship W4387206446A5064186453 @default.
• W4387206446 hasAuthorship W4387206446A5075894849 @default.
• W4387206446 hasAuthorship W4387206446A5086278068 @default.
• W4387206446 hasConcept C126322002 @default.
• W4387206446 hasConcept C126894567 @default.
• W4387206446 hasConcept C143998085 @default.
• W4387206446 hasConcept C146357865 @default.
• W4387206446 hasConcept C151730666 @default.
• W4387206446 hasConcept C155806632 @default.
• W4387206446 hasConcept C2776256026 @default.
• W4387206446 hasConcept C2776694085 @default.
• W4387206446 hasConcept C2778119113 @default.
• W4387206446 hasConcept C2778239845 @default.
• W4387206446 hasConcept C2781451048 @default.
• W4387206446 hasConcept C29730261 @default.
• W4387206446 hasConcept C2989005 @default.
• W4387206446 hasConcept C31760486 @default.
• W4387206446 hasConcept C509974204 @default.
• W4387206446 hasConcept C71924100 @default.
• W4387206446 hasConcept C86803240 @default.
• W4387206446 hasConceptScore W4387206446C126322002 @default.
• W4387206446 hasConceptScore W4387206446C126894567 @default.
• W4387206446 hasConceptScore W4387206446C143998085 @default.
• W4387206446 hasConceptScore W4387206446C146357865 @default.
• W4387206446 hasConceptScore W4387206446C151730666 @default.
• W4387206446 hasConceptScore W4387206446C155806632 @default.
• W4387206446 hasConceptScore W4387206446C2776256026 @default.
• W4387206446 hasConceptScore W4387206446C2776694085 @default.
• W4387206446 hasConceptScore W4387206446C2778119113 @default.
• W4387206446 hasConceptScore W4387206446C2778239845 @default.
• W4387206446 hasConceptScore W4387206446C2781451048 @default.
• W4387206446 hasConceptScore W4387206446C29730261 @default.
• W4387206446 hasConceptScore W4387206446C2989005 @default.
• W4387206446 hasConceptScore W4387206446C31760486 @default.
• W4387206446 hasConceptScore W4387206446C509974204 @default.
• W4387206446 hasConceptScore W4387206446C71924100 @default.
• W4387206446 hasConceptScore W4387206446C86803240 @default.
• W4387206446 hasIssue "2" @default.
• W4387206446 hasLocation W43872064461 @default.
• W4387206446 hasLocation W43872064462 @default.
• W4387206446 hasOpenAccess W4387206446 @default.
• W4387206446 hasPrimaryLocation W43872064461 @default.
• W4387206446 hasRelatedWork W1601338141 @default.
• W4387206446 hasRelatedWork W1974296722 @default.
• W4387206446 hasRelatedWork W2029688276 @default.
• W4387206446 hasRelatedWork W2044910514 @default.
• W4387206446 hasRelatedWork W2067062714 @default.
• W4387206446 hasRelatedWork W2085363994 @default.
• W4387206446 hasRelatedWork W2100029565 @default.
• W4387206446 hasRelatedWork W2348495938 @default.
• W4387206446 hasRelatedWork W2414920248 @default.
• W4387206446 hasRelatedWork W3149859254 @default.
• W4387206446 hasVolume "117" @default.
• W4387206446 isParatext "false" @default.
• W4387206446 isRetracted "false" @default.
• W4387206446 workType "article" @default.